文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

罗特西普对比阿法依泊汀治疗未接受促红细胞生成素、依赖输血的低危骨髓增生异常综合征(COMMANDS):3期开放标签随机对照试验的主要分析

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.
PubMed 文献 · Lancet Haematol · 2024-07-19

COMMANDS试验在26国142中心纳入363例未接受促红细胞生成素、依赖输血的低危骨髓增生异常综合征患者,随机接受罗特西普或阿法依泊汀。罗特西普组达到主要终点(12周以上不依赖红细胞输注且血红蛋白平均升高至少1.5 g/dL)的比例显著高于阿法依泊汀组(60% vs 35%)。罗特西普代表该类患者的新标准治疗。

要点

  • 罗特西普组主要终点达成率60%,阿法依泊汀组35%,差异有统计学意义(p<0.0001)。
  • 罗特西普组3-4级治疗中出现的不良事件常见高血压(10%)、贫血(10%)、肺炎(5%)。
  • 阿法依泊汀组3-4级治疗中出现的不良事件常见贫血(8%)、肺炎(8%)、中性粒细胞减少(6%)。

核心结论

  • 罗特西普代表未接受促红细胞生成素、依赖输血的低危骨髓增生异常综合征患者的新标准治疗。
  • 罗特西普组达到红细胞输注独立和血液学改善的患者显著多于阿法依泊汀组,且在各患者亚组中均观察到获益。

研究设计与样本

  • COMMANDS为3期、开放标签、随机对照试验,在26个国家142个中心开展。
  • 纳入年龄≥18岁、修订版国际预后评分系统定义极低危/低危/中危骨髓增生异常综合征、未接受促红细胞生成素、依赖输血且血清促红细胞生成素浓度<500 U/L的患者。
  • 按基线红细胞输血负荷、血清促红细胞生成素浓度和环形铁粒幼红细胞状态分层,1:1随机分配至罗特西普(1.0-1.75 mg/kg体重,皮下注射,每3周一次)或阿法依泊汀(450-1050 IU/kg体重,皮下注射,每周一次;最大总剂量80000 IU),治疗至少24周。
  • 2019年1月2日至2022年9月29日筛选363例患者并随机分配:罗特西普组182例(50%),阿法依泊汀组181例(50%)。
  • 主要终点在意向治疗人群中评估:至少12周不依赖红细胞输注且同期(第1-24周)平均血红蛋白升高至少1.5 g/dL。

主要发现

  • 罗特西普组达到主要终点的患者比例显著高于阿法依泊汀组:110例(60%)vs 63例(35%);应答率共同风险差25.4%(95%CI 15.8-35.0);p<0.0001。
  • 主要终点中位随访时间:罗特西普组17.2个月(10.4-27.7),阿法依泊汀组16.9个月(10.1-26.6)。
  • 安全性分析中位随访时间:罗特西普组21.4个月(IQR 14.2-32.4),阿法依泊汀组20.3个月(12.7-30.9)。
  • 罗特西普组(n=182)常见3-4级治疗中出现的不良事件:高血压19例(10%)、贫血18例(10%)、肺炎10例(5%)、晕厥10例(5%)、中性粒细胞减少9例(5%)、血小板减少8例(4%)、呼吸困难8例(4%)、骨髓增生异常综合征6例(3%)。
  • 阿法依泊汀组(n=179)常见3-4级治疗中出现的不良事件:贫血14例(8%)、肺炎14例(8%)、中性粒细胞减少11例(6%)、骨髓增生异常综合征10例(6%)、高血压8例(4%)、铁过载7例(4%)、COVID-19肺炎6例(3%)。

关键数值与推荐

  • 主要终点:至少12周不依赖红细胞输注且同期(第1-24周)平均血红蛋白升高至少1.5 g/dL。
  • 罗特西普组主要终点达成率60%(110/182),阿法依泊汀组35%(63/181),风险差25.4%(95%CI 15.8-35.0),p<0.0001。

临床怎么用

  • 作者结论认为罗特西普代表未接受促红细胞生成素、依赖输血的低危骨髓增生异常综合征患者的新标准治疗。
  • 罗特西普组和 阿法依泊汀组中最常见的严重治疗中出现的不良事件均为肺炎(罗特西普组9例[5%],阿法依泊汀组13例[7%])和COVID-19(罗特西普组8例[4%],阿法依泊汀组10例[6%])。
  • interim分析报告了1例死亡(因急性髓系白血病)被认为与罗特西普相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The preplanned interim analysis of the COMMANDS trial showed greater efficacy of luspatercept than epoetin alfa for treating anaemia in erythropoiesis-stimulating agent (ESA)-naive patients with transfusion-dependent, lower-risk myelodysplastic syndromes. In this Article, we report the results of the primary analysis of the trial. METHODS: COMMANDS is a phase 3, open-label, randomised, controlled trial conducted at 142 sites in 26 countries. Eligible patients were those aged 18 years or older, with myelodysplastic syndromes of very low risk, low risk, or intermediate risk (as defined by the Revised International Prognostic Scoring System), who were ESA-naive and transfusion dependent, and had a serum erythropoietin concentration of less than 500 U/L. Patients were stratified by baseline red blood cell transfusion burden, serum erythropoietin concentration, and ring sideroblast status, and randomly allocated (1:1) to receive luspatercept (1·0-1·75 mg/kg body weight, subcutaneously, once every 3 weeks) or epoetin alfa (450-1050 IU/kg body weight, subcutaneously, once a week; maximum total dose 80 000 IU) for at least 24 weeks. The primary endpoint was red blood cell transfusion independence lasting at least 12 weeks with a concurrent mean haemoglobin increase of at least 1·5 g/dL (weeks 1-24), evaluated in the intention-to-treat population. The safety population included all patients who received at least one dose of treatment. This trial is registered with ClinicalTrials.gov (NCT03682536; active, not recruiting). FINDINGS: Between Jan 2, 2019, and Sept 29, 2022, 363 patients were screened and randomly allocated: 182 (50%) to luspatercept and 181 (50%) to epoetin alfa. Median age was 74 years (IQR 69-80), 162 (45%) patients were female, and 201 (55%) were male. 289 (80%) were White, 44 (12%) were Asian, and two (1%) were Black or African American. 23 (6%) were Hispanic or Latino and 311 (86%) were not Hispanic or Latino. Median follow-up for the primary endpoint was 17·2 months (10·4-27·7) for the luspatercept group and 16·9 months (10·1-26·6) for the epoetin alfa group. A significantly greater proportion of patients in the luspatercept group reached the primary endpoint (110 [60%] vs 63 [35%]; common risk difference on response rate 25·4% [95% CI 15·8-35·0]; p<0·0001). Median follow-up for safety analyses was 21·4 months (IQR 14·2-32·4) for the luspatercept group and 20·3 months (12·7-30·9) for the epoetin alfa group. Common grade 3-4 treatment-emergent adverse events occurring among luspatercept recipients (n=182) were hypertension (19 [10%] patients), anaemia (18 [10%]), pneumonia (ten [5%]), syncope (ten [5%]), neutropenia (nine [5%]), thrombocytopenia (eight [4%]), dyspnoea (eight [4%]), and myelodysplastic syndromes (six [3%]); and among epoetin alfa recipients (n=179) were anaemia (14 [8%]), pneumonia (14 [8%]), neutropenia (11 [6%]), myelodysplastic syndromes (ten [6%]), hypertension (eight [4%]), iron overload (seven [4%]), and COVID-19 pneumonia (six [3%]). The most common serious treatment-emergent adverse events in both groups were pneumonia (nine [5%] luspatercept recipients and 13 [7%] epoetin alfa recipients) and COVID-19 (eight [4%] luspatercept recipients and ten [6%] epoetin alfa recipients). One death (due to acute myeloid leukaemia) considered to be luspatercept-related was reported at the interim analysis. INTERPRETATION: Luspatercept represents a new standard of care for ESA-naive patients with transfusion-dependent, lower-risk myelodysplastic syndromes. Significantly more patients had red blood cell transfusion independence and haematological improvement with luspatercept than with epoetin alfa, with benefits observed across patient subgroups. FUNDING: Celgene and Acceleron Pharma.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Della Porta MG, Garcia-Manero G, Santini V, et al. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2024. PMID: 39038479. doi:10.1016/S2352-3026(24)00203-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。